Microbiota intestinal e probióticos: Implicações sobre o câncer de cólon

R. Bedani, E.A. Rossi

 

RESUMO

Atualmente, muito tem se discutido sobre o papel da microbiota intestinal, em particular das bactérias colônicas, na etiologia do câncer de cólon. Evidências revelam que uma microbiota desequilibrada pode contribuir para o desenvolvimento dessa doença. No entanto, estudos têm mostrado que os probióticos podem modular beneficamente a microbiota intestinal do hospedeiro, contribuindo para a inibição da carcinogênese. O presente trabalho tem como propósito apresentar uma revisão sobre a microbiota intestinal e sua relação com a promoção do câncer de cólon, bem como relatar, baseado em evidências científicas, os efeitos benéficos do consumo de probióticos e os possíveis mecanismos pelos quais esses microrganismos poderiam inibir o desenvolvimento desse tipo de câncer.

Palavras-chave: Câncer de cólon; microbiota intestinal; probióticos.

 

SUMMARY

Recently, the role of intestinal microbiota, particularly colonic bacteria, in colon cancer etiology has been widely discussed in scientific literature. Evidence indicate that unbalanced microbiota could contribute to the development of this disease. However, studies have showed that probiotics beneficially modulate intestinal microbiota of host which contributes to an inhibition of carcinogenesis. We review the role of intestinal microbiota on colon cancer promotion, as well as, the potential benefits of probiotics intake in preventing colon cancer and the possible mechanisms envolved.

Keywords: Colon cancer; intestinal microbiota; probiotics.

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

Bibliografia

1. Wang X, Huycke MM. Extracellular superoxide production by Enterococcus faecalis promotes chromossomal instability in mammalian cells. Gastroenterology 2007;132:551-561.        [ Links ]

2. INSTITUTO NACIONAL DE CÂNCER. Estimativa 2008: incidência de Câncer no Brasil. Rio de Janeiro: INCA: 2007. ISBN 978-85-7318-126-5. Disponível em: http://www.inca.gov.br/estimativa/2008/index.asp?link=tabelasestados.asp&UF=BR. Acesso em: 04/01/2008.

3. Hope ME, Hold GL, Kain R, El-Omar EM. Sporadic colorectal cancer – role of the commensal microbiota. FEMS Microbiol Lett 2005; 244:1-7.

4. Grady WM. Genomic instability and colon cancer. Genomic Metastasis Rev 2004;23:11-27.

5. Saad SMI. Probióticos e prebióticos: o estado da arte. Res Bras Ciênc Farm 2006;42:1-16.

6. Rabeneck L, Davila JA, El-Serag HB. Is there a true “shift” to the right colon the incidence of colorectal cancer? Am J Gastroenterol 2003;98:1400-1409.

7. Maskarinec G, Noh JJ. The effect of migration on cancer incidence among Japanese in Havawii. Ethn Dis 2004;14:431-439.

8. Commane D, Hughes R, Shortt C, Rowland I. The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutat Res 2005;591:276-289.

9. Bartram HP, Scheppach W, Schmid H, et al. Proliferation of human colonic mucosa as an intermediate biomarker of carcinogenesis: effects of butyrate, deoxycholate, calcium, ammonia, and pH. Cancer Res 1993;53:3283-3288.

10. Macbain AJ, Macfarlane GT. Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites. J Med Microbiol 1998;47: 407-416.

11. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-519.

12. Macgarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 2005;39:98-109.

13. Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr 1999;69:1046S-1051S.

14. Owen RW, Spiegelhalder B.; Bartsch, H. Generation of reactive oxygen species by the faecal matrix. Gut 2000;46:225-232.

15. Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 2002;23:529-536.

16. Isolauri E, Salminen S, Ouwehand A. Probiotic. Best Pract Res Clin Gastroenterol 2004;18:299-313.

17. Zoetendal EG, Collier CT, Koike S, Mackie RI, Gaskins HR. Molecular ecological analysis of the gastrointestinal microbiota: a review. J Nutr 2004;134:465-472.

18. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004;12:562-568.

19. Boulioux P, Koletzko B, Guarne F, Braesco V. The intestine and its microflora are partners for the protection of the host: reporto n the Danone Symposium “The intelligent Intestine,” held in Paris, June 14, 2002. Am J Clin Nutr 2003;78:675-678.

20. Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007;137:751S-755S.

21. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401-1412.

22. Turton LJ, Drucker DB, Ganguli LA. Effect of glucose concentration in growth medium upon neutral and acidic fermentation endproducts of Clostridium bifermentans, Clostridium sporogenes and Peptostreptococcus anaerobius. Med Microbiol 1993;16: 61-67.

23. Macfarlane GT, Gibson GR, Beaty E, Cummings JH. Estimation of short chain fatty acid production from protein by human intestinal bacteria based on branched-chain fatty acid measurements. FEMS Microbiol Ecol 1992;101: 81-88.

24. Furrie E. A molecular revolution in the study of intestinal microflora. Gut 2006;55:141-143.

25. Guiemonde M, Salminen S. New methods for selecting and evaluating probiotics. Dig Liver Dis 2006; 38: 242 S-247 S.

26. Vaughan EE, Heilig HGHJ, Zoetendal EG, Satokari R, Collins JK, Akkermans ADL, Vos WM. Molecular approaches to study probiotic bacteria. Trends Food Sci Technol 1999;10:400-404.

27. Boyer SL, Flechtner VR, Johansen JR. Is the 16S-23S rRNA internal transcribed spacer region a good tool for use in molecular systematics and population genetics? A case study in cyanobacteria. Mol Biol Evol 2001;18:1057-1069.

28. Sanz J.L, Kochling T. Molecular biology techniques used in waster treatment: an overview. Process Biochem 2007;42:119-133.

29. Malik S, Beer M, Megharaj M, Naidu R. The use of molecular techniques to characterize the microbial communities in contaminated soil and water. Environ Int 2008; 34: 265-276.

30. Ziemer CJ, Gibson GR. An a overview of probiotics, prebiotics and synbiotics in the functional food concept: perspectives and future strategies. Int Dairy J 1998; 8:473-479.

31. Cummings JH, Macfarlane GT. Colonic microflora: nutrition and health. Nutrition 1997;13:476-478.

32. Pryde SE, Duncan SH, Hold G.L, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 2002;17:133-139.

33. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987;28:1221-1227.

34. Csordas A. Butyrate, aspirin and colorectal cancer. Eur J Cancer Prev 1996;5:221-231.

35. Wollowski I., Rechkemmer G, Pool-Zobel, B. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001;73:451S-455S.

36. Segain JP, Raingeard de la Bletiere D.; Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 2000;47:397-403.

37. FAO/WHO. Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, april 30 and may 1, 2002.

38. Saavedra JM. Clinical application of probiotic agents. Am J Clin Nutr 2001;73:1147S-1151S.

39. Mercenier A, Pavan S, Pot B. Probiotic as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Design 2002;8:99-110.

40. Berg RD. Probiotic, probiotics or conbiotics? Trends Microbiol 1998;6:89-92.

41. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR et al. Functional food science of gastrointestinal physiology and function. Br J Nutr 1998;80:147S-171S.

42. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 2003;17:849-859.

43. Goldin BR, Gorbach SL. Alterations of the intestinal microflora by diet, oral antibiotics and Lactobacillus: decreased production of free amines from aromatic nitro compounds, azo dyes and glucuronides. J Natl Cancer Inst 1984;73:689-695.

44. Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998; 52:899-907.

45. Goldin BR. Intestinal microflora: metabolism of drugs and carcinogens. Ann Med 1990;22:43-48.

46. Lidbeck A, Nord CE, Gustafsson JA, Rafter J. Lactobacilli, anticarcinogenic activities and human intestinal microflora. Eur J Cancer Prev 1992;1:341-353.

47. Ling WH, Hänninen O, Mykkänen H, Heikure M, Salminen S, Vonwright A. Colonization and fecal enzyme activities after oral Lactobacillus GG administration in eldery nursing home residents. Ann Nutr Metab 1992;36:162-166.

48. Marteau P, Pochart P, Flourié B, Pellier P, Santos L, Desjeux JF, Rambaud JC. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr 1990;52:685-688.

49. Mital BK, Garg SK. Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Crit Rev Microbiol 1995; 21:175-214.

50. Cole CB, Fuller R, Mallet AK, Rowland IR. The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds. J Appl Bacteriol 1985;69:549-553.

51. Ling WH, Korpela R, Mykkänen H, Salminen S, Hänninen O. Lactobacillus strain GG suplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. J Nutr 1994;124:18-23.

52. Goldin BR, Gorbach S.L. Alterations in fecal microflora enzymes related to diet, age, Lactobacillus supplements, and dimethylhydrazine. Cancer 1977;40:2421-2426.

53. Haberer P, Toit M, Dicks LMT, Ahrens F, Holzapfel WH. Effect of potentially probiotic lactobacilli on faecal enzyme activity in minipigs on high-fat, high-cholesterol diet – a preliminary in vivo trial. Int J Food Microbiol 2003;87:287-291.

54. Benno Y, Mitsuoka T. Impact of Bifidobacterium on human fecal microflora. Microbiol Immunol 1992;36:683-694.

55. Ling W. Diet and colonic microflora interaction in colorectal cancer. Nutr Res 1995;15:439-454.

56. Shahani KM, Ayebo AD. Role of dietary lactobacilli in gastrointestinal microecology. Am J Clin Nutr 1980; 33:2448-2457.

57. Bartram HP, Scheppach W, Gerlach S, Ruckdeschel G, Kelber E. E. Does yoghurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites. Am J Clin Nutr 1994;59:428-432.

58. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc 2001;101:229-241.

59. Zampa A, Silvi S, Fabiani R, Morozzi G, Orpianese C, Cresci A. Effects of different digestible carbohydrates on bile acid metabolism and SCFA production by human gut micro-flora grown in an in vitro semi-continuous culture. Anaerobe 2004; 10:19-26.

60. Moore WE, Moore LH. Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 1997; 91:3202-3207.

61. Knasmuller S, Steinkellner H, Hirschl AM, Rabot S, Nobis EC, Kassie F. Impact of bacteria in dairy products and of the intestinal microflora on the genotoxic and carcinogenic effects of heterocyclic aromatic amines. Mutat Res 2001;480:129-138.

62. Tannock GW, Munro K, Harmsen HJM, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 2000;66:2578-2588.

63. Morotomi M, Mutai M. In vitro binding of potent mutagenic pyrolysates to intestinal bacteria. J Natl Cancer Inst 1986; 77:195-201.

64. Hayatsu H, Hayatsu T. Suppressing effects of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993;73:173-179.

65. Rowland I, Rumney C, Counts J, Lievense L.. Effects of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen induced aberrant crypt foci in rats. Carcinogenesis 1998;19:281-285.

66. Goldin B, Gualtieri L, Moore R. The effect of Lactobacillus GG on the initiation and promotion of DMH induced intestinal tumours in the rat. Nut Cancer 1996;25:197-204.

67. Sivieri K, Spinardi-Barbisan ALT, Barbisan LF, Bedani R, et al. Probiotic Enterecoccus faecium CRL183 inhibit chemically induced colon cancer in male Wistar rats. Eur Food Res Cancer 2008 (online version).

68. Saxelin M, Tynkkynen S, Mattila-Sandholm T, Vos WM. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 2005;16:204-211.

69. Britti MS, Roselli M, Finamore A, Merendino N, Mengheri E. Regulation of immune response at intestinal and peripheral sites by probiotics. Biologia 2006;61:735-740.

70. Neuhaus FC, Baddiley J. A continuum of anionic charge: structures and functions of d-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev 2003;67:686-723.

71. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction. J Biol Chem 1999;274:10689-10692.

72. Watson JL, Mckay DM. The immunophysiological impact of bacterial CpG DNA on the gut Clin Chim Acta 2006;364:1-11.

73. Veckman, V, Miettinen, M, Siren, J, Matikainen S, Julkunen I. Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokins and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol 2004;.75:764-771.

74. Petroff EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB. Probiotics inhibit nuclear factor-κB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition Gatroenterology 2004;127:1474-1487.

75. Philip R, Epstein I. Tumour necrosis factor as immunomodulator and mediator of monocyte citotoxicity induced by itself, γ-interferon and interleukin-γ. Nature 1986;323:86-89.

76. Raitano A, Kore M. Growth inhibition of a human colorectal carcinoma cell line by interleukin-1 associated with enhanced expression of γ-interferon receptors. Cancer Res 1993;53:636-640.

77. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am. J. Gastroenterol 2001;96:574-578.

78. Matzuazaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol 2000; 78:67-73.

79. Nagao F, Nakayama M, Muto T, Okomura K. Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the immune system in healthy human subjects. Biosci Biotechnol Biochem 2000;64:2706-2708.

80. Gill HS, Rutherford KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001;74:833-839.

81. Takagi A, Matsuzaki T.; Sato M, Nomoto K, Morotomi M, Yokokura T. Enhancement of natural killer cell cytotoxicity delayed murine caecinogenesis by a probiotic microorganism. Carcinogenesis 2001;22:599-605.

82. Berman SH, Eichelsdoerfer P, Yim D, Elmer GW, Wenner CA. Daily ingestion of a nutritional probiotic supplement enhances innate immune function in healthy adults. Nutr Res 2006;26:454-459.

83. Matsuzaki, T. Immunomodulation by treatment with Lactobacillus casei strain Shirota. Int J Food Microbiol 1998;16:133–140.

84. Sekine K, Kawashima T, Hashimoto Y. Comparison of the TNF-α levels induced by human-derived Bifidobacterium longum and rat-derived Bifidobacterium animalis in mouse peritoneal cells. Bifidobacteria Microflora 1994;39:79-89.

85. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharm Therap 2003;18:1-5.

86. Perdigón G, Alvarez S, Rachid M, Aguero G, Gobbato N. Symposium: probiotic bactéria for humans; clinical systems for evaluation of effectiveness. Immune system stimulation by probiotics. J Dairy Sci 1995;78:1597-1606.

 

Correspondência:

Raquel Bedani

Departamento de Alimentos e Nutrição

Faculdade de Ciências Farmacêuticas,

Universidade Estadual Paulista

Rodovia Araraquara-Jaú km 1,

Campus Universitário, Caixa Postal 502

CEP 14801-902, Araraquara, Brasil.

Email: raquelbedani@yahoo.com.br

TEL: +55-16-33016922

FAX: +55-16-33016920

 

Recebido para publicação: 06/10/2008

Aceite para publicação: 11/11/2008